Research programme: K-ras oncogenes inhibitors - Astellas/Dana-Farber Cancer Institute
Latest Information Update: 07 Nov 2014
At a glance
- Originator Dana-Farber Cancer Institute
- Developer Astellas Pharma; Dana-Farber Cancer Institute
- Class Small molecules
- Mechanism of Action Ras gene inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Nov 2014 Early research in Cancer in USA (unspecified route)